Researchers said that the results of a clinical study to be presented next month have shown that the blockbuster inhaled lung drug Spiriva, which is marketed by Pfizer and Boehringer Ingelheim reduces heart risk. These findings are contradictory to the conclusion reached earlier by pooled analysis of past studies, which said that Spiriva or tiotropium raised the risk of heart attack, stroke and death from heart disease.